SIL index including stage, soluble interleukin-2 receptor, and LDH is as a useful prognostic predictor in DLBCL

Cancer Science, 05/21/2012

The soluble interleukin index is a simple and objective prognostic index for diffuse large B–cell lymphoma (DLBCL) patients to identify candidates for experimental therapy other than Rituximab (R) plus CHOP chemotherapy (R–CHOP).

Print Article Summary Cat 2 CME Report